Convalescent Plasma / Ahvaz Jundishapur University of Medical Sciences - LARVOL DELTA

The effectiveness of convalescent plasma administered on the first day of admission for COVID-19 patients: an open-label randomized controlled trial. (PubMed, Infect Dis Immun) - "Overall, the treatment appears to have few side effects, suggesting it may be a safe option for further evaluation in managing early COVID-19 symptoms. This prospective, multicenter, two-parallel randomized controlled trial was prospectively registered in the Iranian Clinical Trials Registry (IRCT20200310046736N1)."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases • CRP

The Effects of Convalescent Plasma Transfusion on Serum Levels of Macrophage-Associated Inflammatory Biomarkers in Patients with Severe COVID-19. (PubMed, J Interferon Cytokine Res) - "In addition, real-time PCR data analyses showed that the relative expression of NF-κB2 was significantly declined in the patients who received plasma. The use of convalescent plasma probably has a significant inhibitory effect on the cytokines, chemokines, and inflammatory genes related to macrophage activation, which are closely associated with the worsening of clinical outcomes in severe COVID-19."

Biomarker • Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Respiratory Diseases • CCL3 • IL6 • TNFA • TXNIP

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials. (PubMed, BMC Infect Dis) - "Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care."

Clinical • Journal • Retrospective data • Review • Critical care • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A randomized clinical trial evaluating the immunomodulatory effect of convalescent plasma on COVID-19-related cytokine storm. (PubMed, Intern Emerg Med) - "The length of in-hospital stay, and mortality rate did not significantly reduce in the CP group compared with controls (p > 0.05) while WHO severity scores remarkably improved (p = 0.01), despite the higher frequency of underlying diseases among the CP group (66.7%) vs. controls (33.3%). Although CP has a remarkable immunomodulatory and antiviral potential to improve the cytokine storm and disease severity in COVID-19 patients, it did not considerably affect the mortality rate."

Clinical • Cytokine storm • Journal • Immune Modulation • Infectious Disease • Inflammation • Novel Coronavirus Disease • IFNG • IL10 • IL6 • TNFA